TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory NPM1-mutated Acute My...
What are the key risks (clinical, regulatory, competitive) that could materially affect the stock price after the upcoming data readouts?
What potential partnership or licensing opportunities could arise from the successful Phase 2/3 results, and how might they affect dilution or share price?
How does TUH’s current valuation compare to peers developing similar immuno‑oncology assets, such as anti‑PD‑1/PD‑L1 or other checkpoint inhibitors?
27 days ago